Behaviorism and Mental Health

Alternative perspective on psychiatry's so-called mental disorders | PHILIP HICKEY, PH.D.

  • Home
  • About
  • Contact
  • Tell Your Story
  • Submit Your Story
  • Moderation Policy

Psychiatric-Pharma Business

May 20, 2013 By Phil Hickey |

GBI Research provides business intelligence reports based on “… the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets.” GBI stands for Global Business Intelligence.

I’ve recently come across one of their releases titled Europe Adopting US Strategies to Diagnose and Treat ADHD.

This is essentially a business analysis of the potential sales of ADHD drugs.  Here are some quotes:

“European countries are increasingly adopting the US diagnostic criteria (DSM-IV), resulting in more and more diagnoses of ADHD. Clearer guidelines for diagnosis of ADHD in both adults and children and revisions to ADHD treatment methods will be released in the DSM-V in 2013, superceding [sic] the DSM-IV which was last revised in 2000. This may possibly result in a rise in ADHD diagnoses in the US, and potentially further afield.”

“The US leads the pack in terms of ADHD treatment, holding the highest diagnosis rate for both adults and children. The ADHD market has shown a steady increase in the number of prescriptions in the pediatric population, although this has started to slow down and has potentially reached a plateau. The market will continue to grow, however, due to the increase in the number of adult patients being diagnosed and treated. A relatively open attitude to psychiatric treatment, as well as direct-to-consumer and physician marketing, is leading to increased rates of adult ADHD diagnosis in the US.”

“Currently, disease recognition is much less frequent in Europe than in the US, resulting in a much smaller market size.”

“Although Europe trails behind the US in terms of market revenue, ADHD therapeutics markets are expected to show strong growth, with Spain predicted to witness a Compound Annual Growth Rate (CAGR) of 8% over 2012-2018, beating the US CAGR of 6% during the same future period. European markets have not yet neared the saturation point that ADHD therapeutics are facing in the US, and there is an optimistic view for ambitious growth in this region.”

“The ADHD market in the US was valued at $3,831m in 2011, and is expected to grow to reach $6,260m by 2018. In contrast, the ADHD therapeutics market across France, Germany, Italy, Spain and the UK was valued at $135m in 2011, and is predicted to reach approximately $182m in 2018.”

Of course we’ve always known that psychiatry-pharma is primarily a business operation, but seeing the figures and the projections of this iatrogenic damage being laid out so matter-of-factly makes it seem even more obscene.

Filed Under: A Behavioral Approach to Mental Disorders

About Phil Hickey

I am a licensed psychologist, presently retired. I have worked in clinical and managerial positions in the mental health, corrections, and addictions fields in the United States and England. My wife Nancy and I have been married since 1970 and have four grown children.

 

Recent Articles

  • AND FINALLY
  • RESPONDING TO DR. MOREHEAD’S SECOND ATTACK ON ANTI-PSYCHIATRY
  • DR. PIES STILL TRYING TO EXCULPATE PSYCHIATRY FOR THE CHEMICAL IMBALANCE THEORY OF DEPRESSION
  • RESPONDING TO DANIEL MOREHEAD, MD,  PSYCHIATRY’S LATEST CHAMPION
  • PROBLEMS AT A COLORADO MENTAL HEALTH CENTER
  • THE ENIGMA-MDD PROJECT: SEARCHING FOR THE NEUROPATHOLOGY OF “MAJOR DEPRESSIVE DISORDER”
  • ILLNESSES OR LOOSE COLLECTIONS OF VAGUELY DESCRIBED PROBLEMS?
  • WHY IS PSYCHIATRY SO DEFENSIVE ABOUT CRITICISM OF PSYCHIATRY? Part 2
  • WHY IS PSYCHIATRY SO DEFENSIVE ABOUT CRITICISM OF PSYCHIATRY? Part 1
  • ADDRESSING THE SOCIAL DETERMINANTS OF MENTAL HEALTH – OR PERHAPS NOT

The phrase "mental health" as used in the name of this website is simply a term of convenience. It specifically does not imply that the human problems embraced by this term are illnesses, or that their absence constitutes health. Indeed, the fundamental tenet of this site is that there are no mental illnesses, and that conceptualizing human problems in this way is spurious, destructive, disempowering, and stigmatizing.

Disclaimer

The purpose of this website is to provide a forum where current practices and ideas in the mental health field can be critically examined and discussed. It is not possible in this kind of context to provide psychological help or advice to individuals who may read this site, and nothing written here should be construed in this manner. Readers seeking psychological help should consult a qualified practitioner in their own local area. They should explain their concerns to this person and develop a trusting working relationship. It is only in a one-to-one relationship of this kind that specific advice should be given or taken.

Privacy Policy

Popular Topics…

ADHD akathisia alcohol alcohol/drugs antidepressants antipsychotics anxiety benzodiazepines bipolar books worth reading case study chemical imbalance theory conflict of interest dealing with problems of daily living dementia dependence depression drug DSM DSM-5 ECT expansion of psychiatric turf IF THEY'RE NOT ILLNESSES WHAT ARE THEY? involuntary commitment Mad in America major tranquilizers myth of chemical imbalance myth of mental illness neuroleptics over-medicalization of everyday life parenting pharmaceutical industry placebo posttraumatic stress disorder Psychiatric "spin" research corruption schizophrenia shock "treatment" side effects somatic symptom disorder SSRI's suicide survivors of psychiatry tardive dyskinesia violence

© 2009–2024